FDA Inspection 1298514 — Ipsen Pharma Biotech

Ipsen Pharma Biotech — FEI 3003749112

The FDA completed an inspection of Ipsen Pharma Biotech on March 29, 2024 in Signes. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 29, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Signes (France)

Additional Details

Mutual Recognition Agreement (MRA)